RAB7B as a Potential Therapeutic Target in Liver Cirrhosis: Insights from Protein Expression and Bioinformatics Analyses

Jinyao Dai, Shuaibing Ying, Jie Lin, Yong Pan, Qiudan Zhang, Fang Wang, Yan Lou, Yunqing QiuACS 2025 · DOI

TL;DR

This study identifies RAB7B, a protein involved in cellular waste removal (mitophagy), as a key player in liver cirrhosis progression. By analyzing gene expression data and performing experimental validation, the researchers demonstrate that RAB7B promotes the activation of hepatic stellate cells (HSCs), a major driver of liver fibrosis. This discovery positions RAB7B as a promising therapeutic target for treating liver cirrhosis.

What Problem Does This Paper Address?

Liver cirrhosis is a serious global health issue with limited treatment options beyond liver transplantation. While the role of mitophagy (the process of clearing damaged mitochondria) in liver disease is increasingly recognized, the specific molecular mechanisms and key players in cirrhosis progression remain unclear. This gap hinders the development of novel therapeutic strategies. This paper aims to bridge this gap by identifying mitophagy-related genes that are dysregulated in liver cirrhosis and exploring their potential as therapeutic targets, with a particular focus on their role in hepatic stellate cell (HSC) activation, a critical step in liver fibrosis.

Methods

The researchers employed a multi-pronged bioinformatics and experimental approach:

  • Differential Gene Expression Analysis: They analyzed publicly available gene expression datasets (GSE77627 and GSE139602) to identify genes that are significantly up- or down-regulated in cirrhotic liver tissue compared to healthy controls.
  • Functional Enrichment Analysis: Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses were used to understand the biological pathways and functions associated with the differentially expressed genes (DEGs).
  • Mitophagy Gene Intersection: They cross-referenced the DEGs with known mitophagy-related genes to pinpoint "mitophagy-associated DEGs" (mito-DEGs).
  • Receiver Operating Characteristic (ROC) Analysis: ROC curves were used to assess the diagnostic potential of individual mito-DEGs in distinguishing between cirrhotic and healthy samples.
  • Immune Cell Infiltration Analysis: CIBERSORT was employed to quantify the abundance of different immune cell types in the liver, exploring their relationship with cirrhosis and mito-DEGs.
  • Protein-Protein Interaction (PPI) Networks: STRING and GeneMANIA were used to build networks illustrating how these genes interact with each other.
  • Weighted Gene Coexpression Network Analysis (WGCNA): This technique was used to identify modules of co-expressed genes strongly associated with liver cirrhosis, helping to pinpoint key regulatory genes (hub genes).
  • External Validation: Additional public datasets (GSE25097 and GSE84044) were used to confirm the expression patterns of candidate genes.
  • Experimental Validation:
    • Animal Models: A carbon tetrachloride (CCl4)-induced mouse model of liver cirrhosis was used.
  • Cell Culture: Human hepatic stellate cell line (LX-2) was used to study HSC activation.
  • Molecular Techniques: qRT-PCR, Western blot, immunofluorescence, transwell assays (for migration), EdU assays (for proliferation), and immunohistochemistry were used to assess gene and protein expression, cell behavior, and tissue pathology.
  • Molecular Docking: This computational technique was used to predict the binding affinity of potential therapeutic compounds to RAB7B.

Datasets

  • Gene Expression Omnibus (GEO) datasets:
    • GSE77627 (liver cirrhosis vs. healthy controls)
    • GSE139602 (liver cirrhosis vs. healthy controls)
    • GSE137720 (single-cell RNA sequencing data for liver analysis)
    • GSE25097 (external validation dataset)
    • GSE84044 (external validation dataset)
  • KEGG and Reactome databases: Curated lists of mitophagy-related genes.
  • Human Protein Atlas: Information on protein localization in human tissues.
  • PubChem database: Structures of small-molecule compounds.

Key Insights and Ideas

  • Mitophagy Dysregulation is Central to Cirrhosis: The study strongly implicates impaired mitophagy as a key driver of liver cirrhosis, not just in hepatocytes but also in hepatic stellate cells (HSCs).
  • RAB7B Emerges as a Critical Hub Gene: Through integrative bioinformatics, RAB7B was identified as a central player linking mitophagy dysfunction to liver cirrhosis. Its expression is consistently elevated in cirrhotic tissues and activated HSCs.
  • RAB7B Drives HSC Activation: The research demonstrates that RAB7B actively promotes HSC activation, migration, and proliferation, processes that are fundamental to liver fibrosis. Inhibiting RAB7B effectively attenuates these pro-fibrotic behaviors.
  • RAB7B is a Negative Regulator of Mitophagy: The study provides evidence that RAB7B acts as a negative regulator of mitophagy, meaning its presence hinders the clearance of damaged mitochondria. This dysfunction contributes to the accumulation of damaged mitochondria, exacerbating liver injury.
  • RAB7B Expression is Dynamically Linked to Mitophagy Status: RAB7B levels fluctuate in response to mitophagy activity, increasing when mitophagy is inhibited and decreasing when it's activated, highlighting its responsive role in cellular quality control.
  • Potential for Targeted Therapies: The identification of RAB7B as a key driver and its strong binding affinity with several predicted anti-cirrhosis compounds suggest a promising avenue for developing novel therapeutic interventions.

Key Results

  • 2101 DEGs identified: Between cirrhotic and healthy liver samples.
  • Seven mito-DEGs identified: Including RAB7B, TOMM20, NRAS, HIF1A, CITED2, FIS1, and CSNK2B.
  • RAB7B is upregulated: In cirrhotic liver tissues (both in public datasets and mouse models) and in activated HSCs.
  • RAB7B inhibition attenuates HSC activation: Significantly reduced migration, proliferation, and a-SMA expression in LX-2 cells.
  • RAB7B knockdown restores mitophagy: Reversed TGF-β-induced mitophagy impairment in LX-2 cells.
  • Molecular docking shows strong binding: Between RAB7B and six predicted anti-cirrhosis compounds, with binding energies ranging from -5.3 to -9.1 kcal/mol.

Limitations and Future Work

  • Translational Challenges: The authors acknowledge that the druggability of RAB7B is not yet established, and the structural similarity among RAB GTPases might lead to specificity issues and off-target effects.
  • Preclinical Limitations: Compounds like celastrol have shown adverse effects in preclinical models, necessitating careful evaluation of safety and pharmacokinetics.
  • Limited Sample Size: The reliance on public databases, despite their utility, means the limited sample size might affect the accuracy and reliability of the results.
  • Bioinformatics-Heavy Approach: The study primarily used bioinformatics techniques, and the lack of raw sequencing data requires further validation.
  • Future Directions: The authors emphasize the need for further preclinical studies to assess the safety and efficacy of targeting RAB7B, as well as additional ex vivo and in vivo studies to fully elucidate the molecular processes and mechanisms of RAB7B in liver cirrhosis.

Summary updated

Abstract

Liver cirrhosis remains a major global health challenge, with liver transplantation currently representing the most effective treatment. Elucidating its molecular pathogenesis is therefore critical for the development of novel therapeutic strategies. Emerging evidence indicates that mitophagy plays a pivotal role in cirrhosis progression. In this study, we employed integrative bioinformatics to explore the association between mitophagy and liver cirrhosis, aiming to identify potential therapeutic targets. Differentially expressed genes (DEGs) were obtained from GSE77627 and GSE139602 data sets, followed by functional enrichment analysis. Mitophagy-related differentially expressed genes (mito-DEGs) were screened and assessed through receiver operating characteristic (ROC) analysis, immune cell infiltration profiling, and protein-protein interaction (PPI). Weighted gene coexpression network analysis (WGCNA) identified key modules, and intersecting genes with mito-DEGs highlighted RAB7B as a candidate hub gene, which was validated in external data sets. Experimental verification confirmed elevated RAB7B expression in activated hepatic stellate cells (HSCs) and a mouse model of liver cirrhosis. Functional assays demonstrated that RAB7B inhibition attenuated HSC activation, and molecular docking revealed strong binding affinity between RAB7B and predicted anticirrhosis compounds. We found that RAB7B knockdown restored TGF-β-induced mitophagy inhibition, enhanced mitochondria-lysosome colocalization, and showed dynamic regulation by mitophagy status, indicating its role as a negative and responsive regulator of mitochondrial clearance. Collectively, our findings identify RAB7B as a mitophagy-related hub gene driving liver cirrhosis progression and provide novel insights into its therapeutic potential.
BibTeX
@inproceedings{dai2025rab,
  author = {Jinyao Dai and Shuaibing Ying and Jie Lin and Yong Pan and Qiudan Zhang and Fang Wang and Yan Lou and Yunqing Qiu},
  title = {{RAB7B as a Potential Therapeutic Target in Liver Cirrhosis: Insights from Protein Expression and Bioinformatics Analyses}},
  booktitle = {ACS},
  year = {2025},
  doi = {10.1021/acsomega.5c08027},
}
Figure